• Skip to primary navigation
  • Skip to main content

Convergence Healthcare Advisors

Bulge Bracket Expertise, Boutique Bank Environment

  • Home
  • Team
  • Services
  • Experience
  • News
  • Contact
You are here: Home / Transactions / Sale of Immco Diagnostics to Trinity Biotech
Immco Diagnostics

Immco Diagnostics

Sale of Company to

Trinity Biotech

Terms: $32.75 million
Date Announced: July 2013

Immco, headquartered in Buffalo, New York, and employing 90 people, is a diagnostic company specializing in the development, manufacture and sale of autoimmune test kits on a worldwide basis. Immco’s product line is complemented by specialized reference laboratory services in diagnostic immunology, pathology and immunogenetics, marketed to US-based reference laboratories and hospitals.

Convergence had been engaged by Immco and its financial sponsor Summit Partners, to pursue a sale of the Company. Convergence worked actively with Immco CEO Bill Maggio to craft a strategic marketing plan for the company that maximized value with an optimal acquisition partner. Convergence managed a highly efficient, but fully marketed auction sale process that enabled a closed transaction to be finalized and closed less than 18 weeks after the launch of the process. Ireland-based Trinity Biotech acquired Immco to augment its diagnostics product suite with the addition of Immco’s leading suite of Autoimmune diagnostics products.

The principals of Convergence Healthcare Advisors LLC and Seven Hills Healthcare Advisors LLC are licensed investment banking agents, offering securities through M&A Securities Group, Inc., an unaffiliated broker-dealer. Member FINRA/SIPC. 4151 N. Mulberry Drive, Suite 252 Kansas City, MO 64116.

© 2023 Convergence Healthcare Advisors · Built on the Genesis Framework by AMN Design · Powered by WordPress

Legal Disclosures